Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Satoaki Nakamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5721-3734; OpenAlex author ID A5081250981. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  2. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  3. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  4. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  5. [Chemoradiotherapy for pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.2127↗
  6. [Preoperative chemoradiation for pancreatic cancer]. Co-author PMID 25857006↗
  7. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including g… Co-author DOI 10.1007/s00534-012-0514-x↗
  8. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2011.03.001↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatsuya Ioka · 3 shared papers, 2021–2026 · strength 0.41
  2. Masafumi Ikeda · 3 shared papers, 2021–2026 · strength 0.41
  3. Masato Ozaka · 3 shared papers, 2021–2026 · strength 0.41
  4. Junji Furuse · 3 shared papers, 2021–2026 · strength 0.41
  5. Makoto Ueno · 3 shared papers, 2021–2026 · strength 0.41
  6. Takuji Okusaka · 3 shared papers, 2021–2026 · strength 0.41
  7. Satoshi Kobayashi · 2 shared papers, 2023–2026 · strength 0.32
  8. Nao Fujimori · 2 shared papers, 2023–2026 · strength 0.32
  9. Junki Mizusawa · 2 shared papers, 2021–2026 · strength 0.29
  10. Nobumasa Mizuno · 2 shared papers, 2021–2023 · strength 0.21
  11. Hiroshi Ishii · 2 shared papers, 2021–2023 · strength 0.21
  12. Naohiro Okano · 2 shared papers, 2021–2023 · strength 0.21
  13. Akiko Todaka · 2 shared papers, 2021–2023 · strength 0.21
  14. Nobuyoshi Hiraoka · 2 shared papers, 2021–2023 · strength 0.21
  15. Kentaro Yamazaki · 1 shared paper, 2026 · strength 0.20
  16. Yusuke Sano · 1 shared paper, 2026 · strength 0.20
  17. Yoshito Komatsu · 1 shared paper, 2026 · strength 0.20
  18. Taro Yamashita · 1 shared paper, 2026 · strength 0.20
  19. Yukiko Takayama · 1 shared paper, 2026 · strength 0.20
  20. Kazuo Hara · 1 shared paper, 2026 · strength 0.20
  21. Fumio Nagashima · 1 shared paper, 2026 · strength 0.20
  22. Masashi Kanai · 1 shared paper, 2026 · strength 0.20
  23. Ken Kamata · 1 shared paper, 2026 · strength 0.20
  24. Shin Maeda · 1 shared paper, 2026 · strength 0.20
  25. Kazuyoshi Ohkawa · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.